Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
776.010.04%
QQQ
730.850.03%
BTC/USD
62811.270.3293%
DIA
536.330.09%
GLD
401.810.08%
TLT
82.04-

Protalix BioTherapeutics Inc

PLXAMEX
Trade with Public
Trade with Public
$2.22
-0.14-5.93%
At close: Aug 14, 5:00 PM EST
Earnings: Q2 2026 Earnings were released on Wed Aug 12th, before the market open
Conference Call: The most recent conference call started at 8:00 AM, 4 days ago
Click to view the webcast
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Protalix BioTherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Protalix BioTherapeutics (PLX).

Price Target Range — 4 Quarters

Analyst Consensus — 1 Analysts

1Buy
Consensus RatingBuy# Analysts1Avg. Consensus PT$12

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Mar 19, 2026HC Wainwright & Co.Raghuram SelvarajuMaintainedBuy$12
Nov 21, 2025HC Wainwright & Co.Raghuram SelvarajuPT CutBuy$15→$12
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Protalix BioTherapeutics (AMEX:PLX) with a Buy and maintains $12 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Protalix BioTherapeutics, Lowers Price Target to $12

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Protalix BioTherapeutics (AMEX:PLX) with a Buy and lowers the price target from $15 to $12.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Protalix BioTherapeutics, Raises Price Target to $15

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Protalix BioTherapeutics (AMEX:PLX) with a Buy and raises the price target from $10 to $15.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Protalix BioTherapeutics (AMEX:PLX) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Protalix BioTherapeutics, Raises Price Target to $10

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Protalix BioTherapeutics (AMEX:PLX) with a Buy and raises the price target from $7 to $10.
Benzinga Newsdesk

Watching Protalix BioTherapeutics; Zacks Small-Cap Research Sets $16 Price Valuation

https://scr.zacks.com/files/News/2023/Zacks_SCR_Research_08082023_PLX_Vandermosten.pdf
Happy Mohamed

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved